Theradaptive
Frederick, US · Delaware corporation · 3 known investors
Theradaptive develops protein engineering technology that modifies recombinant proteins into material-binding variants for targeted therapeutic delivery, aiming to improve efficacy and reduce off-target effects. Its applications span more than a dozen clinical indications including spinal fusion, orthopedics, soft tissue repair, and targeted chemotherapeutics.
Founders & leadership
Board
Investors · 3
Funding
SEC filings, press & company announcements$36.2M disclosed across 1 of 3 rounds · 2024–2026
- Undisclosed amountSeries AJul 2025Source ↗
▶$36.2MraisedAug 2026 · 65 investors · BiotechnologyRule 506(b)
- Luis AlvarezExecutive Officer, Director
- David StewartExecutive Officer, Director
- Ted A. MeyersDirector
- George ShanineDirector
- Patrick ZhangDirector
- David HarringtonDirector
- Jeffrey DunnDirector
- Offering amount
- $77.9M
- Amount sold
- $36.2M
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Theradaptive for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseDefense Health Program | Phase II | 2020 | $1.1M |
| Department of DefenseDefense Health Program | Phase I | 2017 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Theradaptive do?
- Theradaptive develops protein engineering technology that modifies recombinant proteins into material-binding variants for targeted therapeutic delivery, aiming to improve efficacy and reduce off-target effects. Its applications span more than a dozen clinical indications including spinal fusion, orthopedics, soft tissue repair, and targeted chemotherapeutics.
- Who founded Theradaptive?
- Theradaptive was founded by Luis Alvarez.
- Who are Theradaptive's investors?
- Theradaptive's investors include Horizons Ventures, Maryland TEDCO, TEDCO.
- How much funding has Theradaptive raised?
- Theradaptive has disclosed $36.2M raised across 1 of its 3 known rounds.
- Where is Theradaptive headquartered?
- Theradaptive is headquartered in Frederick, US.